The prospective, multi-center phase 3 PRIMARY randomized trial tested the additive diagnostic value of PSMA PET imaging in high-risk men with negative or equivocal MRI in the diagnosis of significant ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...
A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.
Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm. The post New state-of-the-art test identifies ...
At the 2026 PSMA and Beyond annual meeting, Robert Reiter discusses the problems with our PSMA PET reports. Dr. Reiter ...
RESTON, Va. - Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...
Add Yahoo as a preferred source to see more of our stories on Google. The scan works by using a molecule that binds to prostate cancer cells, causing them to appear as bright spots on imaging A scan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results